|
|
|
|
 |
Volume 20, No.9
November/December 2004
ARTICLES
Feature 1
Intracranial Aneurysm:
What’s the Latest?
While only a small proportion of the population is affected by intracranial aneurysm, a rupture can be extremely disabling. It is important to be aware of all options with regard to treatment.
By Ciara Harraher, MD; amd Ian G. Fleetwood, MD, FRCSC
Feature 2
Cardiovascular Disease in
Type 2 Diabetes
A “Package” Intervention
This discussion of the Steno-2 trial highlights the benefits “package” intervention offers to patients with Type 2 diabetes who are at high risk of cardiovascular disease.
By Gregory Curnew, MD, CM, FRCPC
ECG of the Month
Unfamiliar Footprints
By Keith J.C. Finnie, MB, ChB, FRCPC
What You Need to Know
An FP’s Review of Current Clinical Trials
VALUE Trial
Peter Lin, MD, CCFP
Cardio Q & A
Experts Answering Your Questions
1. Do recommendations for workup of secondary causes of hypertension vary with age?
2. For a patient with Type 2 diabetes and a normal cholesterol profile, would optimum therapy include a statin?
Cardiovascular News
• Lipitor® prevents cardiovascular disease
• Increased physician accountability for blood
pressure management
• Early diagnosis of congestive heart failure
• New standard for Canadian blood
|
|
Volume 20, No.9
October 2004
ARTICLES
Feature 1
Drug Interactions:
A Method to the Madness
With many cardiac patients taking at least four or five medications, drug interactions are bound to occur. To ensure patient well-being, it is paramount to understand medications and predict interactions before they occur. Dr. Lin lends a hand by reviewing the underlying mechanisms behind drug interactions.
By Peter Lin, MD, CCFP
Feature 2
Hypercoagulability:
When, Who, and How to Investigate
Venous thromboembolism is a common clinical problem, with over two million individuals developing the condition each year in the U.S. alone. Dr. Grewal discusses when, who, and how to investigate for this potentially heart-stopping condition.
By Kuljit Grewal, MD, FRCPC
Feature 3
Battling Chronic Atrial Fibrillation in the Elderly
Despite being the most common sustained cardiac arrhythmia, affecting 5% to 9% of those over the age of 65, atrial fibrillation (AF) remains undertreated, leaving patients exposed to an unnecessarily high stroke risk. The authors discuss AF symptom control and stroke prevention.
By Sara Partington, BA, BSc, MD; and Gregory Curnew, MD,
CM, FRCPC
ECG of the Month
Half The Story
By Keith J.C. Finnie, MB, ChB, FRCPC
Cardio Q & A
1. What about horizontal earlobe creases as markers for CAD?
2. Approaching Dressler’s syndrome?
Cardiovascular News
Teveten® in the reducation of stroke recurrence; First device to measure fluid buildup associated to heart failure; & more...
|
 |
Volume 20, No.8
September 2004
ARTICLES
Feature 1
“Should I take ASA if I do not have blocked arteries?”
By Gregory Curnew, MD, FRCPC
Feature 2
Moving Forward:
Family Physicians & Hypertension
Aproximately four million Canadian adults have hypertension, but only 16% of them are being teated, while 42% are unaware they have it. What role does the family physician play in improving hypertension management?
By R. J. Petrella, MD, PhD
Feature 3
In the Know:
Canadian Guidelines for Dyslipidemia, 2003
Clinical guidelines need to be reassessed to keep up with dislipidemia management. Using new clinical studies, the Canadian Guidelines for Dyslipidemia 2003 tries to adapt cardiovascular risk assessments from across North America.
By Gregory Curnew, MD, FRCPC
CardioCase of the Month
Digoxin Toxicity:
Regaining a Level of Control
By Payam Dehghani, MD, CCFP; and
Andrew Ignaszewski, MD, FRCPC
ECG of the Month
An Unusual Adolescent ECG
By Keith J.C. Finnie, MB, ChB, FRCPC
Cardio Q & A
Cardiovascular News
Study reveals genetic influence on HDL; High-dose Aggrastat® indicated for high-risk patients; & more...
|
 |
Volume 20, No.6
August 2004
ARTICLES
Feature
Hypertension Guidelines Revisited
Despite advancements in therapy and improved education, close to 25% of Canadians today are affected by
hypertension. Which agents are the most effective,
and who will benefit?
By Barry F. Rose, MD, FRCPC
Feature
AF Today:
What Are The Options?
Management strategies for atrial fibrillation should be made on a case by case basis. Pharmacologic treatments seem adequate for most. So, what do recent studies
recommend, and what happens when drug treatment simply does not help?
By Magdy N. Basta, MB, BCh, FRACP
Feature
C-Reactive Protein:
A Look at the Most Recent Studies & Trials
Reprinted from February, 2003
Ischemic heart disease is the world’s leading killer, but new insights involving inflammatory markers could lead to a quicker and more precise diagnosis of its cause.
By Davinder S. Jassal, MD, FRCPC; and
Blair O’Neill, MD, FRCPC, FACC
Cardiovascular Reporter
Survey Says:
Options for Congestive Heart Failure
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
Octopus-shaped Heart?
By Gustavo Nogareda, MD, FSCAI, FACC; and Ken Gin, MD, FRCPC
ECG of the Month
It’s a Small, Small World
By Keith J.C. Finnie, MD, FRCPC
Cardio Q & A
Cardiovascular News
Vacationers at risk of heart attack;
Articulated prosthetic a first in North America; Lipitor® comes out strong & more...
|
 |
Volume 20, No.6
June 2004
ARTICLES
Feature
Revascularization in
CAD Patients
Who Benefits?
Cardiovascular disease accounts for more deaths in Canada than any other disease; half of the deaths are due to CAD. CAD can be treated with revascularization, using techniques such as CABG and PCA. But who benefits from these procedures and when should they be performed?
By Gustavo Nogareda, MD, FSCAI, FACC
Feature
5 Q&As On:
Saving the Brain After Cardiac Arrest
Survival after cardiac arrest is uncommon and patients who do survive have a high incidence of anoxic brain injury. What can be done to manage patients who have been
successfully resuscitated, and is the induction of hypothermia a viable option?
By Robert S. Green, MD, DABEM, FRCPC
Feature
Fibrates in Perspective:
Answering an Age-Old Question
Although fibrates have been used to treat dyslipidemia since the 60s, recent studies have shown their effectiveness in the treatment of hypercholesterolemia, low HDL cholesterol, high triglycerides, and overall cardiovascular risk reduction as well.
By T.K. Lee, FRCPC, MSc, MB, BSc
Cardiovascular Reporter
Problem SOLVD:
Changes in Heart Failure Management
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
Octopus-shaped Heart?
By Payam Dehghani, MD, CCFP; and Andrew P. Ignaszewski, MD, FRCPC
ECG of the Month
See “U” Later
By Martin S. Green, MD, FRCPC
Cardio Q & A
Cardiovascular News
Age not a factor in AF treatment; Bring on the Aspirin®; Added benefits with lipid-lowering drugs & more...
|
 |
Volume 20, No.4
May 2004
Feature
2004 CHEP Hypertension Recommendations:
What’s New, What’s Old But Still Important in 2004
The Canadian Hypertension Education Program recently updated its recommendations for the management of hypertension. Dr. Campbell provides a summary of the key points.
By Norm Campbell, MD;
On behalf of the Canadian Hypertension Education Program
Feature
Troponin:
Marks The Spot!
Cardiac troponins I and T are highly specific markers for myocardial injury. Furthermore, their diagnostic and
prognostic capabilites in ACS have been well established and are important to recognize with regards to treatment options for high-risk patients.
By Jasmine Grewal, MD; and Ken Gin, MD, FRCPC
Cardiovascular Reporter
Atrial Fibrillation: What Are the Options?
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
High Cholesterol: It’s All in the Family
By Bruce Josephson, MD, FRCPC; and Anita Asgar, MD, FRCPC
ECG of the Month
An interval Difference
By Martin S. Green, MD, FRCPC
Cardio Q & A
Clinical Issues in Hypertension
Hypertension: Multidrug Combination Therapy
William Semchuk, MSc, PharmD, FCSHP
Cardiovascular News
Studies show Liptor® effectively reduces cardiac events; A world first in the prevention of aneurysm recurrence; & more...
|
 |
Volume 20, No.4
April 2004
ARTICLES
Feature
This Just In...
An Update on Arrhythmia
What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia.
By Beth L. Abramson, MD, FRCPC, FACC; andIan McAuley Billingsley, MD
Feature
Being Conscious of Syncope
What are the differential diagnoses of syncope? How should patients be managed?
By Gary Klein, MB, BS, FRCPC
Cardiovascular Reporter
Vying For Vitamins
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
Checked Mate
By Bruce Josephson, MD, FRCPC; and Anita Asgar, MD, FRCPC
ECG of the Month
Right-Left Confusion?
By Martin S. Green, MD, FRCPC
Cardio Q & A
Clinical Issues in Hypertension
Automation: Blood Pressure Devices for the Office
Donald W. McKay, PhD; and Ean Parsons, MD, CCFP, FCFP, DipSportMed
Cardiovascular News
Lipitor® can aid in the reduction of heart attacks;
Lovenox® is an effective alternative; & more...
|
 |
Volume 20, No.12
March 2004
ARTICLES
Feature
The Lowdown:
Low HDL and Diabetic Dyslipidemia
Patients with diabetes commonly have an LDL-C no higher than that of the general population. What treatment is warranted to improve their outcome?
By Mary Catherine MacSween, MD, FRCPC
Feature
The Risk of CVD:
How Are Patients With CKD Affected?
Patients with chronic kidney disease (CKD) are considered to be at the highest risk for cardiovascular disease (CVD). How should these patients be treated?
By Ellen Burgess, MD, FACP, FRCPC
Statin Therapy:
Is It Risky Business?
Although statin therapy is generally well tolerated, it should not be undertaken lightly, especially in the primary prevention of cardiovascular disease. What do you need to know about the adverse effects of statin treatment?
By Alun Edwards, BA, MB, BChir, MRCP(UK), FRCPC
Cardiovascular Reporter
MAU to Predict Progression of Atherosclerosis
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
Rate vs. Rhythm
By David Wood, MD; and Kenneth Gin, MD, FRCPC, FACC
ECG of the Month
Timing Isn’t Everything!
By Martin S. Green, MD, FRCPC
Cardio Q & A
This month:
•What is the role of clopidogrel in STEMI?
• What is the current role of CRT in the overall management of severe CHF in Canada today?
Cardiovascular News
XCoricidin II® suitable for hypertensive individuals; Pfizer creates Chair in atherosclerosis; Heart scans play role in predicting risk of heart disease; Erectile dysfunction may be first sign of general vascular disease
|
 |
Volume 19, No.12
February 2004
ARTICLES
Feature
Acute Coronary Syndrome:
Mending the Broken Heart
How should patients with acute coronary syndrome (ACS) be assessed, and what is the common treatment?
By Neil S. Brass, MD, FRCPC
Feature
Interventional Cardiology:
Update on Percutaneous Coronary Intervention
What should you know about new stent technologies and adjunctive drug therapies for coronary intervention? Learn more about these, as well as new innovations in the field of interventional cardiology, in this article.
By Anita W. Asgar, MD, FRCPC; and Michael P. Love, MB, ChB, MRCP(UK), MD
Cardiovascular Reporter
It’s All Greek To Me
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
Mrs. Hess and Her ACS
By Neil S. Brass, MD, FRCPC
ECG of the Month
Which Block Is It?
By Martin S. Green, MD, FRCPC
Clinical Issues in Hypertension
Layman’s Hypertension: How To Talk To Your Patients
Drugs don’t work in patients who don’t take them! How can practitioners provide a clear message to enhance long-term adherence to antihypertensive regimens?
By William Semchuk, MSc, PharmD, FCSHP
Cardio Q & A
Cardiovascular News
Xenical® reduces risk of developing Type 2 diabetes; Blood sugar linked to angioplasty or stenting success rates; Higher doses of ASA associated with higher risk of bleeding; ASA lowers risk of first heart attack by one-third
|
 |
Volume 19, No.12
February 2004
ARTICLES
Feature
Acute Coronary Syndrome:
Mending the Broken Heart
How should patients with acute coronary syndrome (ACS) be assessed, and what is the common treatment?
By Neil S. Brass, MD, FRCPC
Feature
Interventional Cardiology:
Update on Percutaneous Coronary Intervention
What should you know about new stent technologies and adjunctive drug therapies for coronary intervention? Learn more about these, as well as new innovations in the field of interventional cardiology, in this article.
By Anita W. Asgar, MD, FRCPC; and Michael P. Love, MB, ChB, MRCP(UK), MD
Cardiovascular Reporter
It’s All Greek To Me
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
Mrs. Hess and Her ACS
By Neil S. Brass, MD, FRCPC
ECG of the Month
Which Block Is It?
By Martin S. Green, MD, FRCPC
Clinical Issues in Hypertension
Layman’s Hypertension: How To Talk To Your Patients
Drugs don’t work in patients who don’t take them! How can practitioners provide a clear message to enhance long-term adherence to antihypertensive regimens?
By William Semchuk, MSc, PharmD, FCSHP
Cardio Q & A
Cardiovascular News
Xenical® reduces risk of developing Type 2 diabetes; Blood sugar linked to angioplasty or stenting success rates; Higher doses of ASA associated with higher risk of bleeding; ASA lowers risk of first heart attack by one-third
|
 |
Volume 19, No.11
January 2004
ARTICLES
Feature
Be Still My Beating Heart!
An Update on Coronary Disease
Heart disease has long been considered a male health problem, because men are affected at an earlier age than women. However, coronary artery disease (CAD) is the leading cause of death in women. What are the guidelines to assessing, stratifying, and treating CAD in women?
By Beth Abramson, MD, FRCPC, FACC
Feature
Ischemic Heart Disease After 80:
The Heartbeat of the Elderly
How aggressive should lipid and blood pressure lowering be?
By Davinder S. Jassal, MD, FRCPC; and Bruce Josephson, MD, FRCPC, FACC
Cardiovascular Reporter
The Magic of Magnesium
By Gregory P. Curnew, MD, CM, FRCPC
CardioCase of the Month
Statin the Case
By Davinder S. Jassal, MD, FRCPC; and Bruce Josephson, MD, FRCPC, FACC
ECG of the Month
Too Fast or Too Slow?
By Martin S. Green, MD, FRCPC
Clinical Issues in Hypertension
High Blood Pressure: Searching for Resources on the Internet
By R.J. Petrella, MD, PhD; and T. Sebulsky, MD
Cardio Q & A
Cardiology Mailbox
(Letters to the Editor)
|
|
